These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatment of Parkinson's disease: levodopa as the first choice. Katzenschlager R; Lees AJ J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059 [TBL] [Abstract][Full Text] [Related]
5. Levodopa in the early treatment of Parkinson's disease. Murata M Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036 [TBL] [Abstract][Full Text] [Related]
6. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)]. Damier P; Tremblay L; Féger J; Hirsch EC Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093 [TBL] [Abstract][Full Text] [Related]
7. Recent developments in the treatment of Parkinson's disease. Greer M Geriatrics; 1985 Feb; 40(2):34-8, 41. PubMed ID: 2857148 [TBL] [Abstract][Full Text] [Related]
8. Problems with long-term levodopa therapy for Parkinson's disease. Marsden CD Clin Neuropharmacol; 1994; 17 Suppl 2():S32-44. PubMed ID: 9358193 [TBL] [Abstract][Full Text] [Related]
9. [Long-term syndrome in the treatment of parkinsonism with L-dopa and decarboxylase an inhibitor]. Chouza C; Romero S; Gomensoro JB Neurol Neurocir Psiquiatr; 1976; 17(4):255-68. PubMed ID: 828242 [TBL] [Abstract][Full Text] [Related]
10. The drug treatment of Parkinson's disease. Morris JG Aust Fam Physician; 1984 May; 13(5 Suppl):6-8, 11. PubMed ID: 6497767 [TBL] [Abstract][Full Text] [Related]
11. [Drug therapy of parkinsonism]. Teräväinen H; Larsen TA Duodecim; 1982; 98(11):892-900. PubMed ID: 6125373 [No Abstract] [Full Text] [Related]
12. [Current preclinical findings on substances against Parkinson's disease]. Gerlach M; Riederer P Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677 [TBL] [Abstract][Full Text] [Related]
13. [Tiapride in persistent dyskinesias following long-term L-dopa for parkinsonism]. Arlazoroff A; Flechtir S; Goldexberg E; Bleicher Z; Barber Y Harefuah; 1985 Mar; 108(5):227-9. PubMed ID: 4007677 [No Abstract] [Full Text] [Related]
14. Movement disorders with neuroleptic drug treatment. Tarsy D Psychiatr Clin North Am; 1984 Sep; 7(3):453-71. PubMed ID: 6148742 [TBL] [Abstract][Full Text] [Related]
15. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677 [TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy. Fox SH; Chuang R; Brotchie JM Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047 [TBL] [Abstract][Full Text] [Related]
17. Motor complications of Parkinson's disease. Martignoni E; Riboldazzi G; Calandrella D; Riva N Neurol Sci; 2003 May; 24 Suppl 1():S27-9. PubMed ID: 12774208 [TBL] [Abstract][Full Text] [Related]
18. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors]. Cinca I; Serbănescu A; Tudorache B Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452 [No Abstract] [Full Text] [Related]
19. [Combined (surgical and drug) therapy of parkinsonism]. Kandel' EI; Iadgarov IS Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(8):1157-61. PubMed ID: 6388198 [TBL] [Abstract][Full Text] [Related]
20. Management for motor and non-motor complications in late Parkinson's disease. Chan DK; Cordato DJ; O'Rourke F Geriatrics; 2008 May; 63(5):22-7. PubMed ID: 18447408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]